Shares of Incyte Corporation INCY fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
in adult patients with prurigo nodularis, a chronic skin condition characterized by very itchy firm lumps. Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
After hours: March 18 at 6:28:43 PM EDT Loading Chart for INCY ...
After hours: March 14 at 5:13:30 p.m. EDT Loading Chart for INCY ...
After hours: 14 March at 5:13:30 pm GMT-4 Loading Chart for INCY ...
After hours: March 18 at 7:19:22 PM EDT Loading Chart for ZLAB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback